This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Some of the biggest highlights from obesity studies in 2024 included new data on semaglutide and tirzepatide, as well as a new study on risks with sarcopenia. Image: Adobe Stock SURMOUNT-OSA ...

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

This repeated cross-sectional study including 69.2 million obesity management drug dispensed prescriptions revealed an increase from 0.76 million in July 2017 to 1.5 million in February 2024, with an ...

Similarly, tirzepatide has been approved for type 2 diabetes under the name Mounjaro and for obesity under the name Zepbound (or Mounjaro in some regions). On 20 December, tirzepatide also ...

GPs should not prescribe tirzepatide for weight loss until advised to do so by their local ICB, NHS England has said.

Dr. Altagrace Hanley, medical director at La Boussole Medical Spa & Wellness Center, has achieved board certification in ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...